MWVC
NBIX icon

Morgens Waterfall Vintiadis & Co’s Neurocrine Biosciences NBIX Stock Holding History

Morgens Waterfall Vintiadis & Co’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-9,000
Closed -$967K – 47
2019
Q4 		$967K Buy
+9,000
New +$942K 0.66% 37

Other funds holding NBIX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgens Waterfall Vintiadis & Co's NBIX Position: Q1 2020 in Review

Morgens Waterfall Vintiadis & Co sold out of Neurocrine Biosciences (NBIX) in Q1 2020, closing a stake of 9,000 shares — an estimated $967K sold.

Morgens Waterfall Vintiadis & Co first reported a position in NBIX in Q4 2019 and held it in 1 quarter. The position peaked at $967K in Q4 2019. 368 funds tracked by Wall St. Rank hold NBIX as of Q1 2020.

  • Morgens Waterfall Vintiadis & Co reported no remaining Neurocrine Biosciences position as of Q1 2020 after selling out during the quarter.
  • Morgens Waterfall Vintiadis & Co sold 9,000 Neurocrine Biosciences shares in Q1 2020, an estimated $967K.
  • Morgens Waterfall Vintiadis & Co first reported a position in Neurocrine Biosciences in Q4 2019 and held it in 1 quarter.
  • Morgens Waterfall Vintiadis & Co's Neurocrine Biosciences position peaked at $967K in Q4 2019.
  • 368 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2020.

Based on Morgens Waterfall Vintiadis & Co's 13F filing for Q1 2020, filed 15 May 2020.